GSK's Votrient Will Need To Show Efficacy Outweighs Black Box
This article was originally published in The Pink Sheet Daily
Executive Summary
The sixth drug approved to treat renal cell carcinoma, Votrient wins approval just two weeks after a unanimous endorsement from FDA's Oncologic Drugs Advisory Committee.